


(E,E)-Farnesol-d₆

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-Y0248AS | | |
| CAS No.: | 166447-71-8 | | |
| Molecular Formula: | C ₁₅ H ₂₀ D ₆ O | | |
| Molecular Weight: | 228.4 | | |
| Target: | Bacterial; Endogenous Metabolite; Antibiotic; Isotope-Labeled Compounds | | |
| Pathway: | Anti-infection; Metabolic Enzyme/Protease; Others | | |
| Storage: | Pure form | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



BIOLOGICAL ACTIVITY

| | |
|--------------------|--|
| Description | (E,E)-Farnesol-d ₆ is deuterium labeled Farnesol. Farnesol is a sesquiterpene alcohol that modulates cell-to-cell communication in <i>Candida albicans</i> , and has the activity in inhibiting bacteria. |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-217.
- [2]. Cordeiro Rde A, et al. Farnesol inhibits in vitro growth of the *Cryptococcus neoformans* species complex with no significant changes in virulence-related exoenzymes. *Vet Microbiol.* 2012 Oct 12;159(3-4):375-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA